CELLGEBRA LIMITED

Cellgebra is an Irish start‑up at the forefront of oncology drug discovery, harnessing cutting‑edge, data‑driven mathematical algorithms to create digital twins of cancer cells. By simulating the intricate signalling pathways of patient‑derived cell lines grown in 3D culture, the platform enables rapid, low‑cost in‑silico experiments that predict how a tumour will respond to a given therapy.

The company’s suite of services spans the entire drug development pipeline: identifying novel drug targets, testing lead candidates for on‑ and off‑target effects, pinpointing responsive patient populations, exploring promising drug combinations, and forecasting future resistance mechanisms. These capabilities are built on proprietary algorithms and extensive datasets, offering a powerful alternative to traditional, expensive pre‑clinical models.

Backed by Enterprise Ireland and collaborating with the Royal College of Surgeons in Ireland, Cellgebra’s team of experts—led by founder Dr Katja Rybakova, tech lead Dr Souhail Maazioui, and academic co‑founder Prof Brona Murphy—delivers a scientifically rigorous yet accessible solution for pharmaceutical companies and research organisations seeking to improve the success rate of cancer drug development.